CRISPR-phage antibacterials to address the antibiotic resistance crisis: scientific, economic, and regulatory considerations
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
CRISPR-phage antibacterials to address the antibiotic resistance crisis : scientific, economic, and regulatory considerations. / Pacia, Danielle M.; Brown, Beatrice L.; Minssen, Timo; Darrow, Jonathan J.
In: Journal of Law and the Biosciences, Vol. 11, No. 1, lsad030, 01.01.2024.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - CRISPR-phage antibacterials to address the antibiotic resistance crisis
T2 - scientific, economic, and regulatory considerations
AU - Pacia, Danielle M.
AU - Brown, Beatrice L.
AU - Minssen, Timo
AU - Darrow, Jonathan J.
N1 - Funding Information: Timo Minssen’s and Jonathan J. Darrow’s research for this paper was supported by a Novo Nordisk Foundation Grant for a scientifically independent International Collaborative Bioscience Innovation & Law Programme (Inter-CeBIL programme - grant no. NNF23SA0087056). Jonathan J. Darrow also received funding from Arnold Ventures.
PY - 2024/1/1
Y1 - 2024/1/1
N2 - Antibiotic resistance is one of the most dangerous threats to public health. The use of viruses to kill bacteria—phage therapy—has been used for nearly a century but has only recently risen to the forefront of discussion as a potential non-traditional antibacterial that can help to address antibiotic resistant infections. Phage therapy can be augmented using CRISPR (clustered regularly interspaced short palindromic repeats) for tailored bacterial killing. This article assesses the potential of CRISPR-enhanced phage therapy as a product that can address antibiotic resistance, focusing on the economic, legal, and regulatory challenges to its development and availability
AB - Antibiotic resistance is one of the most dangerous threats to public health. The use of viruses to kill bacteria—phage therapy—has been used for nearly a century but has only recently risen to the forefront of discussion as a potential non-traditional antibacterial that can help to address antibiotic resistant infections. Phage therapy can be augmented using CRISPR (clustered regularly interspaced short palindromic repeats) for tailored bacterial killing. This article assesses the potential of CRISPR-enhanced phage therapy as a product that can address antibiotic resistance, focusing on the economic, legal, and regulatory challenges to its development and availability
KW - antibacterials
KW - CRISPR
KW - CRISPR-phage
KW - individualized therapies
KW - new genomic technologies
KW - phage therapies
KW - public health
UR - http://www.scopus.com/inward/record.url?scp=85183863386&partnerID=8YFLogxK
U2 - 10.1093/jlb/lsad030
DO - 10.1093/jlb/lsad030
M3 - Journal article
C2 - 38283616
AN - SCOPUS:85183863386
VL - 11
JO - Journal of Law and the Biosciences
JF - Journal of Law and the Biosciences
SN - 2053-9711
IS - 1
M1 - lsad030
ER -
ID: 386669784